Ultragenyx to Present at BofA Securities Global Health Care Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CFO Shalini Sharp will present at the BofA Securities Global Health Care Conference on May 14, 2020, at 10:20 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CFO Shalini Sharp will present at the BofA Securities Global Health Care Conference on May 14, 2020, at 10:20 AM ET. The event will be available via live and archived webcast on Ultragenyx's website for 90 days post-event. The company focuses on developing therapies for serious rare and ultra-rare genetic diseases, aiming for efficient drug development and urgency in delivering effective treatments to patients with high unmet medical needs.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -1.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will hold a virtual presentation at the BofA Securities Global Health Care Conference on Thursday, May 14, 2020 at 10:20 AM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.